Clinical Development of NLX-101 in Rett Syndrome; estimated costs for filing an IND application

Mark Varney, PhD | Neurolixis

$585,000 AWARDED

Neurolixis is a biotech company developing a drug (NLX-101) to treat breathing problems in Rett Syndrome. John Bissonnette, Ph.D. of OHSU, previously tested the drug in mouse models of Rett. These mice exhibit severe breathing difficulties, including apneas and respiratory irregularity, similar to those seen in girls with Rett syndrome. NLX-101 treatment reduced the occurrence of apneas and normalized the irregular breathing patterns without interfering with other behaviors. These data suggest that NLX-101 may provide significant improvements in breathing regularity in people with Rett Syndrome.

Current Projects